<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804245219
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VERKAZIA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CICLOSPORIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, emulsion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Single Dose Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C Don't Freez
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1324.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Excelvision" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Excelvision
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1022]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Al Hamaed medical company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Santen Oy
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01XA18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Verkazia contains the active ingredient, ciclosporin. Ciclosporin belongs to a group of medicines known as immunosuppressive agents that are used to reduce inflammation.</p><p>&nbsp;</p><p>Verkazia is used to treat children and adolescents aged 4 to 18 years with severe vernal keratoconjunctivitis (an allergic condition of the eye that occurs more frequently in spring and affects the transparent layer in the front part of the eye and the thin membrane covering the front part of the eye).</p><p>&nbsp;</p><p>Verkazia is used to treat adults with severe keratitis (inflammation of the cornea, the transparent layer in the front part of the eye). It is used in those patients who have dry eye disease, which has not improved despite treatment with tear substitutes (artificial tears).</p><p>&nbsp;</p><p>You should visit your doctor at least every 6 months to assess the effect of Verkazia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Verkazia</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ciclosporin or to any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had or have a cancer in or around your eye.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an eye infection.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Only use Verkazia in your eye as described under section 3. Do not exceed the treatment period prescribed by your doctor.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using Verkazia:</p><p>&nbsp;</p><p><em>For treatment of severe VKC</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an eye infection or if you suspect you have an eye infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any other kind of eye disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you wear contact lenses (the use of Verkazia is not recommended with contact lenses).</p><p>&nbsp;</p><p><em>For treatment of severe keratitis in dry eye disease</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have previously had an eye infection by the herpes virus that might have damaged the transparent front part of the eye (cornea).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any medicines containing steroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any medicines to treat glaucoma.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><em>For treatment of severe VKC</em>: Verkazia<em> </em>should not be used in children under the age of 4 years.</p><p><em>For treatment of severe keratitis in dry eye disease</em>: Verkazia<em> </em>should not be used in children and adolescents below 18 years old.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Verkazia</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>Talk to your doctor if you are using eye drops containing steroids administered in association with Verkazia as this association may increase the risk of local infections.</p><p>&nbsp;</p><p>If you are using Verkazia for more than 12 months, you should visit your doctor regularly, e.g., every 3 to 6 months.</p><p>&nbsp;</p><p>If you are using other eye drops, use Verkazia <strong>at least 15 minutes</strong> after using the other eye drops.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p>Verkazia should not be used if you are pregnant. If you could become pregnant you must use contraception while using this medicine.</p><p>&nbsp;</p><p>Verkazia is likely to be present in breast milk in very small amounts. If you are breast feeding talk to your doctor before using this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Your vision may be temporarily blurred after using Verkazia eye drops or you may get other disturbances with your vision. If this happens, wait until your vision clears before you drive or use machines.</p><p>&nbsp;</p><p><strong>Verkazia contains cetalkonium chloride</strong></p><p>Cetalkonium chloride may cause eye irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor</p><p>or pharmacist if you are not sure.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Treatment of severe VKC</em>: A caregiver should help a child starting Verkazia treatment, particularly if the child is aged under 10&nbsp;years, and should continue to supervise the child until the child is able to use Verkazia properly without help. The recommended dose is 1 drop of Verkazia in each affected eye 4 times a day (morning, mid-day, afternoon and evening). You should continue Verkazia as prescribed by your doctor.</p><p>&nbsp;</p><p><em>Treatment of severe keratitis in dry eye disease</em>: One drop in each affected eye, once daily at bedtime.</p><p>&nbsp;</p><p><strong>Instructions for use</strong></p><p>Follow these instructions carefully and ask your doctor or pharmacist if there is anything you do not</p><p>understand.</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="604" height="178" vspace="0" hspace="0" border="0" style="width:604px;height:178px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; If you wear contact lenses, take them out at bedtime before using the drops; you can reinsert them when you wake up.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Open the aluminium pouch, which contains 5 single-dose containers.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Take one single-dose container from the aluminium pouch, leaving the remaining containers in the pouch.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Gently shake the single-dose container.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Twist off the cap<strong> (picture 1).</strong></p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; Pull down your lower eyelid <strong>(picture 2).</strong></p><p>8.&nbsp;&nbsp;&nbsp;&nbsp; Tilt your head back and look up at the ceiling.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp; Gently squeeze one drop of the medicine onto your eye. Make sure that the tip of the single-dose container does not touch your eye.</p><p>10.&nbsp; Blink a few times so that the medicine spreads across your eye.</p><p>11.&nbsp; After using Verkazia, press a finger lightly on the inner corner of your eyelid, next to your nose for 2 minutes <strong>(picture 3). </strong>A small duct that drains tears away from your eye and into your nose is located here. By pressing at this point, you close down the opening of this drainage duct. This helps to stop Verkazia getting into the rest of the body.</p><p>12.&nbsp; If you use drops in both eyes, repeat the steps 6 to 9 for your other eye.</p><p>13.&nbsp; Discard the single-dose container as soon as you have used it, even if there is still some medicine left in it.</p><p>&nbsp;</p><p>If a drop misses your eye, try again.</p><p>&nbsp;</p><p><strong>If you use more Verkazia</strong><strong> than you should, </strong>rinse your eye with water. Do not put in any more drops until it is time for your next regular dose.</p><p>&nbsp;</p><p><strong>If you forget to use Verkazia,</strong> <strong>c</strong><strong>ontinue with the next dose as planned. </strong>Do not take a double dose to make up for the forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Verkazia</strong> without speaking to your doctor,</p><p><em>Treatment of severe VKC</em>: &nbsp;Your eye allergy will not be controlled and could lead to long-term problems with your sight.</p><p><em>Treatment of severe keratitis</em> <em>in dry eye disease</em>: The inflammation of the transparent front part of your eye (known as keratitis) will not be controlled and could lead to impaired vision.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The following side effects have been reported for Verkazia:</strong></p><p>The most common side effects are in and around the eyes.</p><p>&nbsp;</p><p><em><u>Treatment of severe VKC</u></em><u>:</u></p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>Pain when the drops are put into the eye.</p><p><strong>&nbsp;</strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p><em>Common side effects related to the eye:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation and discomfort in or around the eye including a feeling that there is something in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased watering of the eye and blurred vision when the drops are put into the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and redness of eyelid</p><p>&nbsp;</p><p><em>Common</em><em> side effects which are not related to the eye:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the eyelid and of the conjunctiva (thin membrane covering the front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial infection of the cornea (transparent front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye infection caused by herpes zoster virus</p><p>&nbsp;</p><p><em><u>Treatment of severe keratitis in dry eye disease</u></em><u>:</u></p><p><strong>Very common</strong> <strong>(may affect more than 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye irritation</p><p>&nbsp;</p><p><strong>Common</strong><strong> (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Watery eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the conjunctiva (thin membrane covering the front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching in the eye</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discomfort in or around the eye when the drops are put into the eye, including feeling that there is something in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation or swelling of the conjunctiva (thin membrane covering the front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tear disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye discharge</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation or inflammation of the conjunctiva (thin membrane covering the front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the iris (coloured part of the eye) or eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deposits in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abrasion to the outer layer of the cornea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red or swollen eyelids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyst in the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune response or scarring in the cornea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching in the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial infection or inflammation of the cornea (transparent front part of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful rash around the eye caused by the herpes zoster virus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton, on the aluminium pouch label, and on the single-dose containers label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Store below 30 &deg;C.</p><p>&nbsp;</p><p>Keep single-dose containers in the pouch in order to protect from light and avoid evaporation.</p><p>Discard the opened single-dose container immediately after use.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is ciclosporin. One ml of Verkazia contains 1&nbsp;mg of ciclosporin.</p><p>- The other ingredients are medium-chain triglycerides, cetalkonium chloride, glycerol, tyloxapol,</p><p>poloxamer 188, sodium hydroxide (to adjust pH) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Verkazia is a milky white eye drops emulsion. It is supplied in single-dose containers made of a low-density polyethylene (LDPE). Each single-dose container contains 0.3 ml eye drops emulsion.
	The single-dose containers are wrapped in a sealed aluminium pouch.
	
	Pack sizes: 30 and 120 single-dose containers.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Santen Oy, Niittyhaankatu 20, 33720 Tampere, Finland</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>EXCELVISION, 27 Rue de la Lombardi&egrave;re, ZI la Lombardi&egrave;re, 07100 Annonay, France</p><p>&nbsp;</p><p><strong>Manufacturer responsible for batch release</strong></p><p>Santen&nbsp;Oy, Kelloportinkatu 1, 33100 Tampere, Finland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in 01/2025.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيركازيا على المادة الفعالة سيكلوسبورين. وينتمي سيكلوسبورين إلى مجموعة ادوية تُسمى العقاقير المثبطة للمناعة، وهي تُستخدم للحد من الالتهاب.</p><p>&nbsp;</p><p dir="RTL">يُستخدم فيركازيا لعلاج الأطفال والمراهقين في سن 4-18 عامًا من المصابين بالتهاب القرنية والملتحمة الربيعي (حالة حساسية تصيب العين وتحدث بمعدل أكبر في الربيع، وهي تصيب الطبقة الشفافة في مقدمة العين والغشاء الرقيق الذي يغطي مقدمة العين).</p><p>&nbsp;</p><p dir="RTL">يُستخدم فيركازيا لعلاج البالغين المصابين بالتهاب القرنية الشديد (التهاب الطبقة الشفافة في مقدمة العين). وهو يُستخدم في المرضى المصابين بمرض جفاف العين، والذي لا يتحسن رغم العلاج ببدائل الدموع (الدموع الاصطناعية).</p><p>&nbsp;</p><p dir="RTL">ينبغي أن تزور الطبيب كل 6 أشهر على الأقل لتقييم أثر فيركازيا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم فيركازيا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من حساسية تجاه دواء سيكلوسبورين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في الجزء 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالسرطان أو إذا سبقت إصابتك به في العين أو على مقربة منها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى بالعين.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">لا تستخدم فيركازيا في العين إلا حسب الوصف المبين في القسم 3. ولا تتجاوز مدة العلاج الموصوفة بواسطة الطبيب.</p><p>&nbsp;</p><p dir="RTL">استشر الطبيب أو الصيدلي قبل استخدام فيركازيا:</p><p>&nbsp;</p><p dir="RTL">لعلاج التهاب القرنية والملتحمة الربيعي الشديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى بالعين أو إذا كنت تشتبه في ذلك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأي نوع آخر من أمراض العيون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ترتدي عدسات لاصقة (لا يوصى باستخدام فيركازيا مع العدسات اللاصقة).</p><p>&nbsp;</p><p dir="RTL">لعلاج التهاب القرنية الشديد في مرض جفاف العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بعدوى العين بسبب فيروس الحلأ الذي ربما أتلف الطبقة الشفافة في مقدمة العين (القرنية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أي أدوية تحتوي على الستيرويدات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أي أدوية لعلاج الزرَق (المياه الزرقاء).</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />&nbsp;</p><p dir="RTL">لعلاج التهاب القرنية والملتحمة الربيعي الشديد: لا ينبغي استخدام فيركازيا في الأطفال الأصغر من 4 سنوات.</p><p dir="RTL">لعلاج التهاب القرنية الشديد في مرض جفاف العين: ينبغي عدم استخدم فيركازيا في الأطفال والمراهقين الأصغر من 18 عامًا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى مع فيركازيا</strong></p><p dir="RTL">يرجى إخبار طبيبك أو الصيدلي إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">استشر الطبيب إذا كنت تستخدم قطرات عين تحتوي على الستيرويدات وتُعطى إياها مع فيركازيا حيث قد يؤدي هذا الارتباط إلى زيادة خطر الإصابة بالعدوى الموضعية.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تستخدم فيركازيا منذ أكثر من 12 شهرًا، فعليك أن تزور الطبيب بانتظام، أي كل 3-6 شهور.</p><p>&nbsp;</p><p dir="RTL">إن كنت تستعمل قطرات أخرى للعين، فاستخدام فيركازيا بعد <strong>15 دقيقة على الأقل</strong> من استخدام قطرات العين الأخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إن كنتِ حاملًا أو ترضعين طبيعيًا أو تعتقدين أنك قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبك أو الصيدلاني قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">ينبغي عدم استخدام فيركازيا في حالة الحمل. فإذا كان في إمكانكِ الحمل، فعليكِ استخدام موانع حمل أثناء استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">يُرجح أن يوجد فيركازيا في حليب الثدي بكميات ضئيلة للغاية. فإذا كنتِ مرضعة طبيعية، فاستشيري الطبيب قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">قد تتشوش رؤيتك بصورة مؤقتة بعد استخدام قطرات فيركازيا للعين، أو قد تصاب باضطرابات أخرى في بصرك. وإذا حدث ذلك، فانتظر حتى تصفو رؤيتك قبل أن تقود أو تستخدم الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي فيركازيا على كلوريد السيتالكونيوم</strong></p><p dir="RTL">قد يسبب كلوريد السيتالكونيوم تهيج العين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائمًا استعمل هذا الدواء كما أخبرك طبيبك أو الصيدلاني تمامًا. وراجع الطبيب</p><p dir="RTL">أو الصيدلي إذا كنت في شك من أمرك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">علاج التهاب القرنية والملتحمة الربيعي الشديد: على مقدم الرعاية مساعدة الطفل الذي يبدأ العلاج باستخدام فيركازيا إذا كان الطفل أصغر من 10 سنوات، وينبغي أن يستمر في الإشراف على الطفل إلى أن يستطيع الطفل استخدام فيركازيا بطريقة صحيحة ودون مساعدة. الجرعة الموصى بها هي قطرة واحدة من فيركازيا في كل عين مصابة 4 مرات في اليوم (الصباح، منتصف النهار، بعد الظهر والمساء). يجب عليك الاستمرار في استخدام فيركازيا كما وصف الطبيب.</p><p>&nbsp;</p><p dir="RTL">علاج التهاب القرنية الشديد في مرض جفاف العين: قطرة واحدة في كل عين مصابة، مرة يوميًا، قبل النوم.</p><p>&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL">اتبع هذه التعليمات بعناية واستشر الطبيب أو الصيدلي إذا كان هناك ما لا تفهمه.</p><p><img src="data:image/png;base64,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" alt="" width="604" height="178" vspace="0" hspace="0" border="0" style="width:604px;height:178px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong>يرجى غسل اليدين.</p><p dir="RTL"><strong>2.&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت ترتدي عدسات لاصقة، فانزعها قبل النوم وقبل استخدام القطرات، ويمكنك إعادة وضعها في العين عندما تستيقظ.</p><p dir="RTL"><strong>3.&nbsp;&nbsp;&nbsp;&nbsp; </strong>افتح الكيس المصنوع من الألومنيوم، والذي يحتوي على خمس عبوات صغيرة أحادية الجرعة.</p><p dir="RTL"><strong>4.&nbsp;&nbsp;&nbsp;&nbsp; </strong>خذ عبوة واحدة من العبوات أحادية الجرعة من داخل الكيس المصنوع من الألومنيوم واترك العبوات الأخرى داخله.</p><p dir="RTL"><strong>5.&nbsp;&nbsp;&nbsp;&nbsp; </strong>رج العبوة أحادية الجرعة برفق.</p><p dir="RTL"><strong>6.&nbsp;&nbsp;&nbsp;&nbsp; </strong>لف الغطاء <strong>(الصورة 1).</strong></p><p dir="RTL"><strong>7.&nbsp;&nbsp;&nbsp;&nbsp; </strong>اسحب جفن العين السفلي إلى أسفل <strong>(الصورة 2).</strong></p><p dir="RTL"><strong>8.&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمِل رأسك إلى الخلف وانظر إلى أعلى في اتجاه السقف.</p><p dir="RTL"><strong>9.&nbsp;&nbsp;&nbsp;&nbsp; </strong>اعصر برفق قطرة واحدة من الدواء إلى عينك. وتأكد من أن طرف العبوة أحادية الجرعة لا يلامس عينك.</p><p dir="RTL"><strong>10.&nbsp; </strong>ارمش بضع مرات حتى يتوزع الدواء على عينك.</p><p dir="RTL"><strong>11.&nbsp; </strong>بعد استخدام فيركازيا، اضغط بإصبعك برفق على الركن الداخلي من جفنك، إلى جوار أنفك، لمدة دقيقتين <strong>(الصورة 3)</strong>. ستنضح قناة صغيرة الدموع من العين إلى الأنف في ذلك الموضع، وأنت تعلق فتحة قناة التصريف. يساعد ذلك على منع وصول فيركازيا إلى بقية الجسم.</p><p dir="RTL"><strong>12.&nbsp; </strong>إذا كنت تستخدم القطرات في كلتا العينين، فكرر الخطوات من 6 إلى 9 للعين الأخرى.</p><p dir="RTL"><strong>13.&nbsp; </strong>تخلص من العبوة أحادية الاستخدام فور استخدامك إياها، حتى لو تبقى فيها بعض الدواء.</p><p>&nbsp;</p><p dir="RTL">إن أخطأت في وضع القطرة، فجرب مجددًا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكبر من اللازم من فيركزايا،</strong> فاشطف عينك بالماء. ولا تضع أي قطرات إضافية حتى يحين وقت الجرعة المقررة التالية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام فيركازيا، فاستمر في الجرعة التالية حسب المخطط.</strong> ولا تستخدم جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL"><strong>لا توقف استخدام فيركازيا</strong> دون التحدث مع طبيبك أولًا.</p><p dir="RTL">علاج التهاب القرنية والملتحمة الربيعي الشديد: لن يمكن السيطرة على حساسية عينك ويمكن أن يؤدي ذلك إلى مشكلات طويلة الأمد في بصرك.</p><p dir="RTL">علاج التهاب القرنية الشديد في مرض جفاف العين: التهاب الجزء الأمامي الشفاف من عينك (يسمى التهاب القرنية) لن تجري السيطرة عليه وقد يؤدي إلى قصور البصر.</p><p>&nbsp;</p><p>إن كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، فاسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، بالرغم من أنها لا تصيب الجميع.<br />&nbsp;</p><p dir="RTL"><strong>وردت تقارير بشأن الآثار الجانبية التالية مع فيركازيا:</strong></p><p dir="RTL">كانت الآثار الجانبية الأكثر شيوعًا في العينين وعلى مقربة منهما.</p><p>&nbsp;</p><p dir="RTL"><u>علاج التهاب القرنية والملتحمة الربيعي الشديد</u><u>:</u></p><p dir="RTL"><strong>شائعة جدًا (قد تؤثر على أكثر من 1 في كل 10 أشخاص)</strong></p><p dir="RTL">ألم عند وضع القطرات في العين.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</strong><br />&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة المرتبطة بالعين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج والانزعاج في العين أو على مقربة منها، بما في ذلك الشعور بوجود شيء ما في العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إدماع العين وتشوش البصر عند وضع القطرات في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم جفن العين واحمراره</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية <em>الشائعة غير المرتبطة بالعين:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص)</strong><br />&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم جفن العين والملتحمة (الغشاء الرقيق الذي يغطي مقدمة العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية بالقرنية (الجزء الأمامي الشفاف من العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى العين بسبب عدوى الحلأ النطاقي</p><p>&nbsp;</p><p dir="RTL"><u>علاج التهاب القرنية الشديد في مرض جفاف العين</u><u>:</u></p><p dir="RTL"><strong>شائعة جدًا</strong> <strong>(قد تؤثر على أكثر من 1 في كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</strong><br />&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار جفن العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدماع العينين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش البصر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم جفن العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الملتحمة (الغشاء الرقيق الذي يغطي مقدمة العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرش في العين</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص)</strong><br />&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاج في العين أو على مقربة منها عند وضع القطرات في العين، بما في ذلك الشعور بوجود شيء ما في العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج أو التورم في الملتحمة (الغشاء الرقيق الذي يغطي مقدمة العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب دمعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز من العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج أو الالتهاب في الملتحمة (الغشاء الرقيق الذي يغطي مقدمة العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القزحية (الجزء الملون من العين) أو جفن العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترسبات في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سحجة في الطبقة الخارجية من القرنية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجفنين أو تورمهما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيسة في جفن العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استجابة مناعية أو تندب في القرنية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرش في جفن العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية أو الالتهاب بالقرنية (الجزء الأمامي الشفاف من العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المؤلم بسبب فيروس الحلأ النطاقي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن زادت حدة أي من الآثار الجانبية، أو إن لاحظت تعرضك لأي آثار غير مدرجة في<br />هذه النشرة، فيرجى إبلاغ طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والكيس المصنوع من الألومونيوم، وعلى ملصق العبوات أحادية الجرعة بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.<br />&nbsp;</p><p dir="RTL">لا ينبغي تجميده.</p><p>&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">احتفظ بالعبوات أحادية الجرعة في الكيس لحمايتها من الضوء ولتجنب التبخر.</p><p dir="RTL">تخلص من العبوة أحادية الجرعة المفتوحة فور استخدامها.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف أو النفايات المنزلية. استفسر من الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها. تحافظ هذه الإجراءات على البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات فيركازيا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">- المادة الفعالة هي سيكلوسبورين. يحتوي كل واحد مل من فيركازيا على 1 ملجم من سيكلوسبورين.</p><p dir="RTL">- تتضمن المكونات الأخرى الدهون الثلاثية متوسطة السلسلة، وكلوريد السيتالكونيوم، والجليسرول، والتيلوكسابول،</p><p dir="RTL">وبولوكسامير 188، وهيدروكسيد الصوديوم (لضبط الرقم الهيدروجيني)، وماء للحقن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>شكل فيركازيا ومحتويات العبوة</strong><br />&nbsp;</p><p dir="RTL" style="text-align:right">فيركازيا مستحلب قطرات عين &nbsp;أﺑﯿﺾ حليبي. وهو يتوفر في عبوات أحادية الجرعة مصنوعة من البولي إيثيلين منخفض الكثافة (LDPE). وكل عبوة أحادية الجرعة تحتوي على 0.3 مل من مستحلب القطرات.</p><p dir="RTL" style="text-align:right">تُلف العبوات أحادية الجرعة في كيس مغلق من الألومونيوم.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">أحجام العلب: 30 و120 عبوة أحادية الجرعة.</p><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل تفويض التسوق</strong></p><p dir="RTL">سانتين أوي، نيتيهانكاتو 20، 33720 تامبير، فنلندا</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">اكسلفيجن، 27 ريو دي لا لومباردير، زي لا لومبارديير، 07100 أنوناي، فرنسا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة مسؤولة عن إصدار الدفعة</strong></p><p dir="RTL">سانتين أوي، كيلوبورتينكاتو 1، 33100 تامبير، فنلندا<strong> </strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة مؤخرًا في 01/2025.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Verkazia 1 mg/ml eye drops, emulsion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of emulsion contains 1 mg of ciclosporin.
Excipient with known effect:
One ml of emulsion contains 0.05 mg cetalkonium chloride.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, emulsion.
Milky white emulsion.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Treatment of severe vernal keratoconjunctivitis (VKC)</u></p><p>Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.</p><p>&nbsp;</p><p><u>Treatment of severe keratitis in dry eye disease</u></p><p>Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Verkazia treatment should only be initiated by an ophthalmologist or a healthcare professional qualified in ophthalmology.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em><u>Treatment of severe VKC</u></em></p><p><em>Children from 4 years of age and adolescents</em></p><p>The recommended dose is one drop of Verkazia 4 times a day (morning, noon, afternoon and evening) to be applied to each affected eye during the VKC season.&nbsp;If signs and symptoms of VKC persist after the end of the season, the treatment can be maintained at the recommended dose or decreased to one drop twice daily once adequate control of signs and symptoms is achieved. Treatment should be discontinued after signs and symptoms are resolved, and reinitiated upon their recurrence.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Missed dose</em></p><p>If a dose is missed, treatment should be continued on the next instillation as normal. Patients should be advised not to instill more than one drop for each instillation in the affected eye(s).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of Verkazia in children below 4 years in the treatment of severe vernal keratoconjunctivitis.</p><p><em>&nbsp;</em></p><p><em><u>Treatment of severe keratitis in dry eye disease</u></em></p><p><em>&nbsp;</em></p><p><em>Adults</em></p><p>The recommended dose is one drop of Verkazia once daily to be applied to the affected eye(s) at bedtime.</p><p>Response to treatment should be reassessed at least every 6 months.</p><p>&nbsp;</p><p>If a dose is missed, treatment should be continued on the next day as normal. Patients should be advised not to instil more than one drop in the affected eye(s).</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>The elderly population has been studied in clinical studies. No dose adjustment is required.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of Verkazia in children and adolescents aged below 18 in the treatment of severe keratitis in dry eye disease, which has not improved despite treatment with tear substitutes.</p><p><em>&nbsp;</em></p><p><em>Patients with renal or hepatic impairment</em></p><p>The effect of Verkazia has not been studied in patients with renal or hepatic impairment. However, no special dose adjustment is needed in these populations.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Ocular use.</p><p>&nbsp;</p><p><em>Precautions to be taken before administering the medicinal product</em></p><p>Patients should be instructed to first wash their hands.</p><p>Prior to administration, the single-dose container should be gently shaken.</p><p>&nbsp;</p><p>For single use only. Each single-dose container is sufficient to treat both eyes.</p><p>&nbsp;</p><p>Patients should be instructed to use nasolacrimal occlusion and to close the eyelids for 2 minutes after instillation, to reduce the systemic absorption. This may result in a decrease in systemic undesirable effects and an increase in local activity.</p><p>&nbsp;</p><p>If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 15 minutes apart. Verkazia should be administered last (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Ocular or peri-ocular malignancies or premalignant conditions.
Active or suspected ocular or peri-ocular infection.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Treatment of severe VKC</u></p><p><strong>&nbsp;</strong></p><p><em><u>Contact lenses</u></em></p><p>Patients wearing contact lenses have not been studied<em>. </em>Therefore, the use of Verkazia with contact lenses is not recommended.</p><p>&nbsp;</p><p><em><u>Concomitant therapy</u></em></p><p>Co-administration of Verkazia with eye drops containing corticosteroids may potentiate the effects of Verkazia on the immune system. However, in clinical studies, 18 patients received Verkazia (4 times daily) in co-administration with eye drops containing corticosteroids and no increase in the risk of adverse reactions related to the immune system was identified. Therefore, caution should be exercised when corticosteroids are administered concomitantly with Verkazia.</p><p>&nbsp;</p><p><em><u>Effects on the immune system</u></em></p><p>Ophthalmic medicinal products, which affect the immune system, including ciclosporin, may affect host defences against local infections and malignancies. Therefore, regular examination of the eye(s) is recommended, e.g. every 3 to 6 months, when Verkazia is used for more than 12 months.</p><p>&nbsp;</p><p>Verkazia has not been studied in patients with an active orofacial herpes simplex infection, a history of ocular herpes, varicella-zoster, or vaccinia virus infection and should therefore be used with caution in such patients.</p><p>&nbsp;</p><p><u>Treatment of severe keratitis in dry eye disease</u></p><p>Verkazia has not been studied in patients with a history of ocular herpes and should therefore be used with caution in such patients.</p><p>&nbsp;</p><p><em><u>Contact lenses</u></em></p><p>Patients wearing contact lenses have not been studied. Careful monitoring of patients with severe keratitis is recommended. Contact lenses should be removed before instillation of the eye drops at bedtime and may be reinserted at wake-up time.</p><p>&nbsp;</p><p><em><u>Concomitant therapy</u></em></p><p>There is limited experience with Verkazia in the treatment of patients with glaucoma. Caution should be exercised when treating these patients concomitantly with Verkazia, especially with beta-blockers which are known to decrease tear secretion.</p><p>&nbsp;</p><p><em><u>Effects on the immune system</u></em></p><p>Medicinal products, which affect the immune system, including ciclosporin, may affect host defences against infections and malignancies.</p><p>Co-administration of Verkazia with eye drops containing corticosteroids could potentiate the effects of Verkazia on the immune system.</p><p>&nbsp;</p><p><u>Excipient</u></p><p>Verkazia contains cetalkonium chloride which may cause eye irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with Verkazia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/contraception in females</u></p><p>Verkazia is not recommended in women of childbearing potential not using effective contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data from the use of &nbsp;Verkazia in pregnant women.</p><p>Studies in animals have shown reproductive toxicity following systemic administration of ciclosporin at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to the clinical use of Verkazia.</p><p>&nbsp;</p><p>Verkazia is not recommended during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Following systemic absorption, ciclosporin is excreted in breast milk. There is insufficient information on the effects of ciclosporin in newborns/infants. However, at therapeutic doses of ciclosporin in eye drops, it is unlikely that sufficient amounts would be present in breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Verkazia therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of Verkazia on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Verkazia has moderate influence on the ability to drive and use machines.</p><p>This medicinal product may induce temporary blurred vision or other visual disturbances which may affect the ability to drive or use machines (see section&nbsp;4.8). Patients should be advised not to drive or use machines until their vision has cleared.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em><u>Treatment of severe VKC</u></em></p><p>The most common adverse reactions with Verkazia are eye pain (11%) and eye pruritus (9%) which are usually transitory and occurred during instillation.</p><p>&nbsp;</p><p><em><u>Treatment of severe keratitis in dry eye disease</u></em></p><p>In five clinical studies including 532 patients who received ciclosporin 1 mg/ml eye drops emulsion and 398 who received vehicle (control), ciclosporin 1&nbsp;mg/ml eye drops emulsion was administered at least once a day in both eyes, for up to one year. The most common adverse reactions were eye pain (19.2%), eye irritation (17.8%), lacrimation (6.4%), ocular hyperaemia (5.5%) and eyelid erythema (1.7%) which were usually transitory and occurred during instillation.</p><p>The majority of adverse reactions reported in clinical studies with the use of ciclosporin 1&nbsp;mg/ml eye drops emulsion were ocular and mild to moderate in severity.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions listed below were observed in clinical studies or during post-marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>Treatment of severe VKC</u></em></p><p><em><u>&nbsp;</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Keratitis bacterial,</p><p>Herpes zoster ophthalmic.</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Eye pain.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Eye pruritus,</p><p>Ocular hyperaemia,</p><p>Eye irritation,</p><p>Ocular discomfort,</p><p>Foreign body sensation in eyes,</p><p>Lacrimation increased,</p><p>Vision blurred,</p><p>Erythema of eyelid,</p><p>Eyelid oedema.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blepharitis, conjunctival oedema.</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cough.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Treatment of severe keratitis in dry eye disease</u></em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Keratitis bacterial,</p><p>Herpes zoster ophthalmic.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Eye pain,</p><p>Eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erythema of eyelid,</p><p>Lacrimation increased,</p><p>Ocular hyperaemia,</p><p>Vision blurred,</p><p>Eyelid oedema,</p><p>Conjunctival hyperaemia,</p><p>Eye pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Conjunctival oedema,</p><p>Lacrimal disorder,</p><p>Eye discharge,</p><p>Conjunctival irritation,</p><p>Conjunctivitis,</p><p>Foreign body sensation in eyes,</p><p>Deposit eye,</p><p>Keratitis,</p><p>Blepharitis,</p><p>Chalazion,</p><p>Corneal infiltrates,</p><p>Corneal scar,</p><p>Eyelid pruritus,</p><p>Iridocyclitis.</p><p>Ocular discomfort</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Instillation site reaction</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Headache</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;SFDA Call Center: 19999</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;E-mail: npc.drug@sfda.gov.sa</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;Website: http://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>For <strong>United Arab Emirates</strong>, you can report any side effects through the Ministry of health and prevention:</p><p>Pharmacovigilance and Medical Device Section</p><p>P.O.Box : 1853</p><p>Tel: 800011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health and Prevention</p><p>Dubai, U.A.E</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- &nbsp;&nbsp;&nbsp;&nbsp;Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Systemic exposure to Verkazia following topical ocular administration has been shown to be negligible. If overdose with Verkazia occurs, it may be flushed from the eye(s) with water and treatment should be symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, other ophthalmologicals, ATC code: S01XA18</p><p>&nbsp;</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>Following ocular administration, ciclosporin is passively absorbed by T-lymphocytes where its binding to cyclophilin A inactivates calcineurin, and prevents nuclear factor of activated T cells (NF-AT) translocation into the nucleus, thus blocking the release of pro-inflammatory cytokines such as IL-2 and hence T-lymphocyte activation. Blocking NF-AT also interferes in the allergy process. Ciclosporin inhibits histamine release from mast cells and basophils through a reduction in IL-5 production, and may reduce eosinophil recruitment and effects on the conjunctiva and cornea. Ciclosporin is also known to up-regulate the release of anti-inflammatory cytokines. All available evidence suggests that ciclosporin acts specifically and reversibly on lymphocytes and does not depress haematopoiesis or have any effect on the function of phagocytic cells.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><u>&nbsp;</u></p><p><em><u>Treatment of severe vernal keratoconjunctivitis (VKC)</u></em></p><p>In a 12 month double-masked, vehicle controlled, pivotal clinical trial (VEKTIS study), 169 patients with severe VKC and severe keratitis (grade 4 or 5 on the modified Oxford scale) were randomised to 4 drops of ciclosporin 1 mg/ml eye drops emulsion (high dose) or 2 drops of ciclosporin 1 mg/ml eye drops emulsion (low dose) and 2 drops of vehicle or 4 drops of vehicle for the first 4 months (Period 1). Patients randomised to the vehicle group were switched to ciclosporin 1 mg/ml eye drops emulsion (four times or twice daily) from Month 4 to Month 12 (Period 2).</p><p>&nbsp;</p><p>168 patients [127 children (75.6%) and 41 adolescents (24.4%)] were included in the efficacy analyses. Mean age was 9.2 years (SD: 3.3, age range: 4-17 years). There were more male [n=132 (78.6%)] than female patients [n=36 (21.4%)].</p><p>&nbsp;</p><p>The primary efficacy endpoint which was the average penalties adjusted change of the Corneal Fluorescein Staining (CFS) score from baseline and over Period 1, considered all patients (n=168). Efficacy was assessed every month during the 4 month treatment period and compared with baseline using a composite criterion based on keratitis assessed by the modified Oxford scale, the need for rescue medicinal product (use of topical steroids) and the occurrence of corneal ulceration.</p><p>&nbsp;</p><p>The difference in the Least Square (LS) mean vs. vehicle was 0.76 (95% CI: 0.26, 1.27) for the high dose group and 0.67 (95% CI: 0.16, 1.18) for the low dose group. Both differences were statistically significant with p=0.007 for the high dose and p=0.010 for the low dose group.</p><p>&nbsp;</p><p>Clinical relevance of the primary efficacy endpoint was however difficult to address. In that context, responder rate&rsquo;s results were considered as more reliable endpoint. A responder was defined as a patient 1) with a mean CFS score over the 4 months of treatment &le; 50% of baseline, 2) who did not withdraw from the study for a reason possibly due to treatment, 3) with no experience of corneal ulceration and 4) no use of rescue medicinal product in the last 4 months of treatment. There was a significantly higher number of CFS responders in both active groups as compared to vehicle (p=0.005 for the high dose group, and p=0.010 for the low dose group) with 55.4%, 50.0% and 27.6% of responders in the high dose, low dose and vehicle groups respectively. The excess rate with respect to vehicle was 27.8% for the high dose regimen and 22.4% for the low dose one.</p><p>&nbsp;</p><p>Rescue medicinal product (topical steroids) was used more often in the vehicle than in the high dose regimen: 32.1% in the high dose group and 31.5% in the low dose group received at least one course of rescue medicinal product while they were 53.4% in the vehicle group.</p><p>&nbsp;</p><p>All four symptoms (photophobia, tearing, itching and mucous discharge) improved over time and the difference from baseline at Month 4 for each symptom largely exceeded 10 mm.</p><p>&nbsp;</p><p>For the average of VKC symptoms, the difference in the LS mean vs. vehicle in the high dose group was statistically significant at all time points compared to vehicle: -19.4 mm (p&lt;0.05).</p><p><em>&nbsp;</em></p><p>Patient quality of life (Quick questionnaire) improved significantly better in the high dose group compared to vehicle. The improvement was clinically relevant as illustrated by the effect size over 4&nbsp;months (symptoms domain: 0.67 and daily activities domain: 0.44).</p><p>&nbsp;</p><p>In Period 2, analyses demonstrated stability of improvements achieved during Period 1 for both doses regimen.</p><p>&nbsp;</p><p><em><u>Treatment of severe kertaitis in dry eye disease</u></em></p><p>The efficacy and safety were evaluated in two randomised, double-masked, vehicle-controlled clinical studies in adult patients with dry eye disease (keratoconjunctivitis sicca) who met the International Dry Eye Workshop (DEWS) criteria.</p><p>&nbsp;</p><p>In the 12&nbsp;month, double-masked, vehicle controlled, pivotal clinical trial (SANSIKA study), 246&nbsp;Dry Eye Disease (DED) patients with <strong>severe</strong> keratitis (defined as a corneal fluorescein staining (CFS) score of 4 on the modified Oxford scale) were randomised to one drop of ciclosporin 1&nbsp;mg/ml eye drops emulsion or vehicle daily at bedtime for 6 months. Patients randomised to the vehicle group were switched to ciclosporin 1&nbsp;mg/ml eye drops emulsion after 6&nbsp;months. The primary endpoint was the proportion of patients achieving by Month 6 at least a two-grade improvement in keratitis (CFS) <u>and</u> a 30% improvement in symptoms, measured with the Ocular Surface Disease Index (OSDI). The proportion of responders in the ciclosporin 1&nbsp;mg/ml eye drops emulsion group was 28.6%, compared to 23.1% in the vehicle group. The difference was not statistically significant (p=0.326).</p><p>The severity of keratitis, assessed using CFS, improved significantly from baseline at Month 6 with ciclosporin 1&nbsp;mg/ml eye drops emulsion compared to vehicle (mean change from baseline was -1.764 with ciclosporin 1&nbsp;mg/ml eye drops emulsion <em>vs.</em> -1.418 with vehicle, p=0.037) . The proportion of ciclosporin 1&nbsp;mg/ml eye drops emulsion -treated patients with a 3-grade improvement in CFS score at Month 6 (from 4 to 1) was 28.8%, compared to 9.6% of vehicle-treated subjects, but this was a post-hoc analysis, which limits the robustness of this outcome. The beneficial effect on keratitis was maintained in the open phase of the study, from Month 6 and up to Month&nbsp;12. &nbsp;</p><p>The mean change from baseline in the 100-point OSDI score was ‑13.6 with ciclosporin 1&nbsp;mg/ml eye drops emulsion and ‑14.1 with vehicle at Month 6 (p=0.858). In addition, no improvement was observed for ciclosporin 1&nbsp;mg/ml eye drops emulsion compared to vehicle at Month 6 for other secondary endpoints, including ocular discomfort score, Schirmer test, use of concomitant artificial tears, investigator&rsquo;s global evaluation of efficacy, tear break-up time, lissamine green staining, quality of life score, and tear osmolarity.</p><p>A reduction in the ocular surface inflammation assessed with Human Leukocyte Antigen-DR (HLA-DR) expression (an exploratory endpoint), was observed at Month 6 in favour of ciclosporin 1&nbsp;mg/ml eye drops emulsion(p=0.021).</p><p>&nbsp;</p><p>In the 6&nbsp;month, double-masked, vehicle controlled, supportive clinical trial (SICCANOVE study), 492&nbsp;DED patients with <strong>moderate to severe</strong> keratitis (defined as a CFS score of 2 to 4) were also randomised to ciclosporin 1&nbsp;mg/ml eye drops emulsion or vehicle daily at bedtime for 6 months.&nbsp; The co-primary endpoints were the change in CFS score, and the change in global score of ocular discomfort unrelated to study medication instillation, both measured at Month 6. A small but statistically significant difference in CFS improvement was observed between the treatment groups at Month 6 in favour of ciclosporin 1&nbsp;mg/ml eye drops emulsion (mean change from baseline in CFS -1.05 with ciclosporin 1&nbsp;mg/ml eye drops emulsion and -0.82 with vehicle, p=0.009).</p><p>The mean change from baseline in ocular discomfort score (assessed using a Visual Analogic Scale) was -12.82 with ciclosporin 1&nbsp;mg/ml eye drops emulsion &nbsp;and -11.21 with vehicle (p=0.808).</p><p>&nbsp;</p><p>In both studies, no significant improvement of symptoms was observed for ciclosporin 1&nbsp;mg/ml eye drops emulsion compared to vehicle after 6&nbsp;months of treatment, whether using a visual analogue scale or the OSDI.</p><p>&nbsp;</p><p>In both studies one third of the patients in average had Sj&ouml;gren&rsquo;s syndrome; as for the overall population, a statistically significant improvement in CFS in favour of ciclosporin 1&nbsp;mg/ml eye drops emulsion was observed in this subgroup of patients.</p><p>&nbsp;</p><p>At completion of the SANSIKA study (12 month study), patients were asked to enter the Post SANSIKA study. This study was an open-label, non-randomized, one-arm, 24-month study extension of the Sansika Study. In Post SANSIKA study patients alternatively received ciclosporin 1&nbsp;mg/ml eye drops emulsion treatment or no treatment depending on CFS score (patients received ciclosporin 1&nbsp;mg/ml eye drops emulsion when there was a worsening of keratitis).</p><p>This study was designed to monitor the long-term efficacy and relapse rates in patients who have previously received ciclosporin 1&nbsp;mg/ml eye drops emulsion.</p><p>The primary objective of the study was to assess the duration of the improvement following ciclosporin 1&nbsp;mg/ml eye drops emulsion treatment discontinuation once the patient was improved with respect to the baseline of the SANSIKA study (i.e. at least 2 grade improvement on the modified Oxford scale).</p><p>67 patients were enrolled (37.9% of the 177 patients having ended Sansika). After the 24-month period, 61.3% of 62 patients included in the primary efficacy population did not experience a relapse based on CFS scores. Percentage of patients who experienced a severe keratitis recurrence was 35% and 48% in patients treated 12 months and 6 months with ciclosporin 1&nbsp;mg/ml eye drops emulsion respectively in the SANSIKA study.</p><p>Based on the first quartile (the median could not be estimated due to the small number of relapses), time to relapse (back to CFS grade 4) was &le;224 days and &le;175 days in patients previously treated 12&nbsp;months and 6 months with ciclosporin 1&nbsp;mg/ml eye drops emulsion, respectively. Patients spent more time on CFS grade 2 (Median 12.7 weeks/year) and grade 1 (Median 6.6 weeks/year) than CFS grade 3 (Median 2.4&nbsp;weeks/year), CFS grades 4 and 5 (Median time 0&nbsp;week/year).</p><p>Assessment of DED symptoms by VAS showed a worsening of patient&rsquo;s discomfort from the time treatment was first stopped to the time it was restarted except pain which remained relatively low and stable.&nbsp; The median global VAS score increased from the time treatment was first stopped (23.3%) to the time treatment was restarted (45.1%).</p><p>No significant changes have been observed in the other secondary endpoints (TBUT, lissamine green staining and Schirmer test, NEI-VFQ and EQ-5D) over the course of the extension study.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Verkazia in all subsets of the paediatric population for dry eye disease (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal pharmacokinetic studies have not been conducted in humans with Verkazia.</p><p>&nbsp;</p><p><u>Treatment of severe vernal keratoconjunctivitis (VKC)</u></p><p>Blood concentrations of ciclosporin 1&nbsp;mg/ml eye drops emulsion were measured using a specific high-pressure liquid chromatography-mass spectrometry assay. In 166 patients with VKC at baseline from one efficacy study (55 patients in the high dose group, 53 in the low dose group and 58 in the vehicle group), plasma concentrations of ciclosporin were measured before administration and after 2, 4 and 12&nbsp;months of treatment.</p><p>In the high dose group after 4 months of ocular instillation of ciclosporin 1&nbsp;mg/ml eye drops emulsion 4 times daily, the maximum quantifiable value detected in the 14 patients who had quantifiable levels of cyclosporine was 0.670&nbsp;ng/ml which is considered to be a negligible value. At Month 12, the maximum quantifiable value detected in the 12 patients who had quantifiable levels of cyclosporine was 0.291 ng/ml which is considered to be a negligible value.</p><p>&nbsp;</p><p>In the low dose group, after 4 months of ocular instillation of ciclosporin 1&nbsp;mg/ml eye drops emulsion 2 times daily, the maximum quantifiable value detected in the 5 patients who had quantifiable levels of cyclosporine was 0.336&nbsp;ng/ml which is considered to be a negligible value. At Month 12, the maximum quantifiable value detected in the 5 patients who had quantifiable levels of cyclosporine was 0.300 ng/ml which is considered to be a negligible value.</p><p>&nbsp;</p><p><u>Treatment of severe kertaitis in dry eye disease</u></p><p>In 374 dry eye disease patients from the two efficacy studies, plasma concentrations of ciclosporin were measured before administration and after 6 months (SICCANOVE study and SANSIKA study) and 12 months of treatment (SANSIKA study). After 6 months of ocular instillation of ciclosporin 1&nbsp;mg/ml eye drops emulsion once per day, 327 patients had values below the lower limit of detection (0.050 ng/ml) and 35 patients were below the lower limit of quantification (0.100 ng/ml). Measurable values not exceeding 0.206 ng/ml were measured in eight patients, values considered to be negligible. Three patients had values above the upper limit of quantification (5 ng/ml) however they were already taking oral ciclosporin at a stable dose, which was allowed by the studies&rsquo; protocol. After 12 months of treatment, values were below the low limit of detection for 56 patients and below the low limit of quantification in 19&nbsp;patients. Seven patients had measurable values (from 0.105 to 1.27 ng/ml), all considered to be negligible values. Two patients had values above the upper limit of quantification, however they were also on oral ciclosporin at a stable dose since their inclusion in the study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, phototoxicity and photoallergy, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medium-chain triglycerides</p><p>Cetalkonium chloride</p><p>Glycerol</p><p>Tyloxapol</p><p>Poloxamer 188</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not freeze.</p><p>Store below 30 &deg;C.</p><p>Keep single-dose containers in the pouch in order to protect from light and avoid evaporation.</p><p>Discard the opened single-dose container immediately after use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.3&nbsp;ml single-dose, low-density polyethylene (LDPE) containers in a sealed laminate aluminium pouch.</p><p>One pouch contains 5 single-dose containers.</p><p>Pack sizes of 30 or 120 single-dose containers.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Santen Oy
Tampere, Finland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>